2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Related Products

PDF 0.8 MB

Indoleamine 2, 3-dioxygenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. To date, three types of tryptophan-metabolizing enzymes have been identified: IDO1, IDO2 and tryptophan 2,3-dioxygenase 2.

IDO is an intracellular enzyme that is constitutively expressed in several human and mouse cells. Being present in innate immune cells, such as Mos and dendritic cells (DCs), IDO catalyzes the initial rate-limiting step of tryptophan (Trp) catabolism, thus leading to the production of immunoregulatory catabolites (collectively known as kynurenines).

The IDO gene promoter contains multiple sequence elements that confer responsiveness to proinflammatory mediators, thereby demonstrating the strong correlation between inflammation and induced IDO expression.

Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148511
    Vidutolimod
    		Activator
    Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator. Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer.
    Vidutolimod
  • HY-112867
    Amg-1
    		Inhibitor
    Amg-1 is a potent, reversible and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor (IC50 = 3.0 μM). Amg-1 exhibits >80-fold selectivity over IDO2 (IC50 > 250 μM) and >20-fold selective over TDO (IC50 > 62.5 μM). Amg-1 can be used for cancer, hypotension, and neurological disorders research.
    Amg-1
  • HY-N0110A
    Palmatine
    		Inhibitor
    Palmatine is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities.
    Palmatine
  • HY-170322
    TDO2-IN-1
    TDO2-IN-1 is a selective TDO2 inhibitor. TDO2-IN-1 binds to the active pocket, heme-binding pocket and substrate-binding pocket of apo-TDO2, interacts with key residues, competitively inhibits heme insertion, and suppresses intracellular TDO2 activity. TDO2-IN-1 can be used in research related to cancer, metabolism and other fields.
    TDO2-IN-1
  • HY-18770A
    IDO-IN-6
    		Inhibitor 99.80%
    IDO-IN-6 (NLG-1486) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, Compound 1486, has an IC50 of <1 μM.
    IDO-IN-6
  • HY-W834359
    (±)-Longamide
    		Inhibitor 99.20%
    (±)-Longamide is a polycyclic bioactive metabolite isolated from sponges that has several bromopyrrole fragments, as well as a weak inhibitor of IDO1.
    (±)-Longamide
  • HY-15760R
    Necrostatin-1 (Standard)
    		Inhibitor
    Necrostatin-1 (Standard) is the analytical standard of Necrostatin-1. This product is intended for research and analytical applications. Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM). Necrostatin-1 is also an IDO inhibitor.
    Necrostatin-1 (Standard)
  • HY-145332
    IDO1-IN-11
    		Inhibitor
    IDO1-IN-11 is an IDO1 inhibitor with an IC50 value of 0.6 nM.
    IDO1-IN-11
  • HY-112147
    IDO1 and HDAC1 Inhibitor
    		Inhibitor
    IDO1 and HDAC1 Inhibitor (Compound 10) is a dual IDO1 and HDAC1 inhibitor with IC50s of 69.0 nM and 66.5 nM, respectively.
    IDO1 and HDAC1 Inhibitor
  • HY-134583
    IDO1-IN-7
    		Inhibitor
    IDO1-IN-7 is a highly potent and selective indoleamine-2,3-dioxygenase-1 (IDO1) inhibitor, with an IC50 of 6.1 nM in in the cellular assay (SKOV3). IDO1-IN-7 has immunomodulatory effects. IDO1-IN-7 can be used for the research of cancer.
    IDO1-IN-7
  • HY-110387
    IDO-IN-9
    		Inhibitor
    IDO-IN-9 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.011 μM (Kinase) and 0.0018 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 6.
    IDO-IN-9
  • HY-111234
    IDO-IN-11
    		Inhibitor
    IDO-IN-11 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 13.
    IDO-IN-11
  • HY-145280A
    IDO1/2-IN-1 hydrochloride
    		Inhibitor
    IDO1/2-IN-1 hydrochloride (compound 4t) is the first potent IDO1/IDO2 dual inhibitor with IC50s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 hydrochloride exhibits antitumor activies. Orally active.
    IDO1/2-IN-1 hydrochloride
  • HY-148173
    NUCC-0223619
    		Inhibitor
    NUCC-0223619 is an IDO1 inhibitor, induce degradation of IDO protein. NUCC-0223619 can be used to synthesis PROTAC.
    NUCC-0223619
  • HY-144468
    IDO1-IN-17
    		Inhibitor
    IDO1-IN-17 (I-4) is an IDO1 inhibitor, with an IC50 of 0.44 μM in hela cells.
    IDO1-IN-17
  • HY-146674
    IDO1/TDO-IN-3
    		Inhibitor
    IDO1/TDO-IN-3 is a potent inhibitor of IDO1/TDO. IDO1/TDO-IN-3 exhibits significant activities against IDO1 (IC50: 0.005 μM) and TDO (IC50: 0.004 μM). IDO1/TDO-IN-3 shows considerable in vivo anti-tumor activity and no obvious toxicity is observed.
    IDO1/TDO-IN-3
  • HY-172453
    XW-032
    		Inhibitor
    XW-032 is an apo-IDO1 inhibitor, with an IC50 of 21 nM. XW-032 (TGI = 63%) exhibits potent in vivo anti-tumor efficacy in the CT26 syngeneic mouse model and is expected to be applied in the research of the field of cancer.
    XW-032
  • HY-162962
    IDO1/TDO-IN-7
    		Inhibitor
    IDO1/TDO-IN-7 (Compound 43b), an isoquinoline derivative, is a potent dual IDO1/TDO inhibitor, with IC50s of 0.31 μM and 0.08 μM, respectively. IDO1/TDO-IN-7 displays acceptable pharmacokinetic profiles and potent antitumor efficacy with low toxicity in B16-F10 tumor model.
    IDO1/TDO-IN-7
  • HY-139883
    IDO-IN-15
    		Inhibitor
    IDO-IN-15 is an IDO1 inhibitor (IC50 < 0.51 nM).
    IDO-IN-15
  • HY-N0353R
    Curdione (Standard)
    Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
    Curdione (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.